Wells Fargo & Company Cuts Septerna (NASDAQ:SEPN) Price Target to $11.00

Septerna (NASDAQ:SEPN) had its price target dropped by investment analysts at Wells Fargo & Company from $14.00 to $11.00 in a research report issued on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 75.75% from the company’s current price.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th.

Septerna Stock Down 0.5 %

SEPN traded down $0.03 during midday trading on Friday, reaching $6.26. The company’s stock had a trading volume of 9,225 shares, compared to its average volume of 455,111. The firm has a fifty day simple moving average of $10.17. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.08). The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.13 million. As a group, analysts anticipate that Septerna will post -7.11 earnings per share for the current year.

Insider Activity

In related news, CFO Gil M. Labrucherie purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The shares were acquired at an average price of $5.85 per share, with a total value of $29,250.00. Following the purchase, the chief financial officer now directly owns 30,000 shares in the company, valued at $175,500. This represents a 20.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Alan Ezekowitz purchased 41,355 shares of the stock in a transaction on Thursday, March 6th. The stock was bought at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the transaction, the director now directly owns 104,101 shares of the company’s stock, valued at approximately $624,606. This trade represents a 65.91 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 74,346 shares of company stock worth $439,670.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. Tower Research Capital LLC TRC acquired a new stake in shares of Septerna during the 4th quarter worth about $25,000. New York State Common Retirement Fund bought a new stake in Septerna during the fourth quarter worth about $32,000. Legal & General Group Plc acquired a new stake in shares of Septerna during the fourth quarter worth approximately $42,000. Summit Investment Advisors Inc. bought a new position in shares of Septerna in the fourth quarter valued at approximately $45,000. Finally, BNP Paribas Financial Markets acquired a new stake in Septerna during the 4th quarter valued at $52,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.